Institutional Sign In

Go

Amgen Czech Republic - Balance Sheet

Assets and their Funding (CZK mil)
Pharmaceutical | Czechia | April 2, 2020
$10.99
Excel Sheet

Amgen Czech Republic's total assets reached CZK 261 mil at the end of 2017, down 11% compared to the previous year.

Current assets amounted to CZK 260 mil, or 99.6% of total assets while cash stood at CZK 0.283 mil at the end of 2017.

By contrast, total debt reached CZK 0 mil at the year-end, or 0% of total assets, while the firm's equity amounted to CZK 192 mil. As a result, net debt stood at CZK -0.283 mil at the end of 2017 and accounted for -0.147% of equity.

Net debt against equity is up 0.147 pp from five years ago (0%). The ratio against EBITDA increased from 0x seen in 2012 to -0.006x.

The company’s cost of funding amounted to in 2017, down 475 pp compared to the average over the last 5 years.

You can see all the company’s data at Amgen Czech Republic profile, or you can download a report on the company in the report section.